Physician profile
James W Dailey
NPI 1730120759
$10,483.23
in general payments reported to CMS, 2019-2025
42 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $827 · 2021: $789 · 2022: $1,328 · 2023: $1,756 · 2024: $1,986 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,367.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,931.81 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,549.82 | 2019-2025 | Otezla, Evenity, Repatha |
| Abbvie INC. | $1,316.41 | 2021-2025 | Vraylar, Linzess, Creon |
| Novo Nordisk INC | $783.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $745.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.72 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $558.90 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $473.33 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $328.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $203.42 | 2023-2024 | Freestyle Libre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.91 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $191.01 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $167.63 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.95 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.24 | 2019-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.